Sign In
Buy PRME
$2.92
-0.100 (-3.31%)
At Close: Jul 31, 2026
Prime Drink Group Provides Bi-Weekly MCTO Status Report
08:00pm, Friday, 29'th Aug 2025
MONTREAL, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, 2025 and August 15, 2025,
Prime Medicine to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 26'th Aug 2025
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Drink Group Provides Bi-Weekly MCTO Status Report and Announces Closing of Private Placement
08:44pm, Friday, 15'th Aug 2025
MONTREAL, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news release date July 30, 2025, the Company voluntaril
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
10:11am, Thursday, 07'th Aug 2025
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.46 per share a year ago.
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
08:00am, Thursday, 07'th Aug 2025
-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interact
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
04:01pm, Friday, 01'st Aug 2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine Announces Pricing of Public Offering
09:33pm, Wednesday, 30'th Jul 2025
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Drink Group Extends Expiry Date of Its Rights Offering and Announces Delay in Filing Annual Financial Statements
08:59pm, Wednesday, 30'th Jul 2025
MONTREAL, July 30, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that, pursuant to a notice of variation dated July 29, 2025 (the “Notice
Prime Medicine Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 30'th Jul 2025
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
10:55am, Wednesday, 30'th Jul 2025
After reaching an important support level, Prime Medicine, Inc. (PRME) could be a good stock pick from a technical perspective. PRME recently experienced a "golden cross" event, which saw its 50-day s
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
10:45am, Wednesday, 30'th Jul 2025
An updated edition of the June 27, 2025, article.
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy
08:10am, Wednesday, 16'th Jul 2025
BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy fo
-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the
Prime Medicine: Pressing Forward With Lead Liver Targeting Indications
04:45pm, Monday, 07'th Jul 2025
Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds, but is pivoting to larger in-vivo gene editing liver disease targeting opportunities. PRME is priorit
